Noninfectious Uveitis of the Posterior Segment | Treatment Algorithms: Claims Data Analysis | US | 2019

Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis is typically treated successfully with topical corticosteroids, noninfectious uveitis of the posterior segment (NIU-PS) can be more difficult to manage. Corticosteroids (e.g., topical, systemic) remain the clinical mainstay for this type of uveitis, but the use of other immunomodulators, such as tumor necrosis factor (TNF)-alpha inhibitors, has become increasingly widespread. Given the competitive NIU-PS therapy market, it is essential to understand the use of current therapies in the nuanced treatment algorithm using real-world data.


  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed NIU-PS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NIU-PS patients?
  • How has AbbVie’s Humira, which was approved for noninfectious intermediate, posterior, and panuveitis in 2016, been integrated into the treatment algorithm, and what is its source of business?
  • What proportion of NIU-PS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of NIU-PS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with NIU-PS?


Geographies: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Humira, Remicade, other TNF-alpha inhibitors, Ozurdex, Iluvien, Retisert, Lotemax, Durezol, Triesence, prednisolone, prednisone

Key analysis provided:

Brand/therapy usage across longitudinal patient sample

Newly diagnosed patient analysis

Treatment initiation and progression

Line of therapy analysis

Combination therapy analysis

Source of business for recently treated patients

Persistency and compliance analysis

Product-level patient flowcharts


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Login to access report

launch Related Market Assessment Reports